$RBB

[144] RBB Bancorp SEC Filing

This SEC filing ([144] Form) by RBB Bancorp (RBB) reports a proposed sale of 6,000 shares of common stock, acquired via a stock option grant on April 29, 2026. The aggregate market value of these shares is $144,363, with the sale expected around April 29, 2026, on NASDAQ. The filing indicates a neutral impact and sentiment.

Original reporting
Published Apr 29, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RBB
Neutral
high confidence
Mentioned
$RBB
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$RBBNeutralLow
01

Why it matters

The transaction is small and explicitly labeled as neutral, suggesting limited market impact.

02

Market read

The news has minimal relevance for traders due to its small scale and neutral sentiment.

03

What to watch

Potential future filings or disclosures could alter the perception; also, market conditions at the time of sale may influence stock response.

Relevance 6/10Timing: low

Background

RBB Bancorp's SEC filing details a minor stock sale, which is a routine disclosure for compliance and transparency.

Company-level read

Ticker impact

$RBBNeutralHigh confidence
Context

High relevance due to direct SEC filing involving stock sale.

Expected impact

Minimal to no significant price movement expected in the short term.

Evidence & confidence

The transaction involves a relatively small number of shares and is explicitly reported as neutral in impact and sentiment, indicating no substantial change in market perception or valuation.

Market effects

Limited; no sector-wide impact anticipated from this individual transaction.

Minimal; localized effect with no broader regional implications.

Negligible; no global market impact expected.

Counterpoint

While the filing appears neutral, some traders might interpret the sale as a potential signal of insider confidence or liquidity needs, which could be cautiously monitored.

Key entities

  • RBB Bancorp

    A regional bank holding company.

Related articles

Med

RBB Bancorp Q2 2026 Earnings Call Summary

RBB Bancorp reported Q2 2026 net income up 13% year over year, citing improved credit quality, loan and deposit growth, and capital actions. Sequential net income fell due to lower REO sale gains. Management expects net interest margin to improve in 2H 2026, aided by $40m sub-debt redemption and higher-yielding loan growth, and targets resolving a $19.4m REO asset in 2H 2026.

$RBBMed

RBB Bancorp Reports Second Quarter 2026 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share

RBB Bancorp (RBB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_970512.htm EXHIBIT 99.1 ex_970512.htm Exhibit 99.1 RBB Bancorp Reports Second Quarter 2026 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share Los Angeles, CA, July 20 , 20 26 – RBB Bancorp (NASDAQ:RBB) and its bank subsidiary, Royal Business Bank

$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.